Brisbane
Brisbane
Brisbane, California, United States6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Atacicept in Subjects With IgA Nephropathy | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT04716231 | |
| Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, bone marrow disorder, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, myelodysplastic syndrome, myeloid leukemia, neoplasm | Active, not recruiting | Not stated | 2026-09-03 | NCT04635384 | |
| Atacicept in Multiple Glomerular Diseases | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, focal segmental glomerulosclerosis, glomerulonephritis, immune system disorder, kidney disorder, macular corneal dystrophy, nephritis, nephrosis, nephrotic syndrome, urinary system disorder | Recruiting | Phase 2 | 2026-06-26 | NCT06983028 | |
| A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Enrolling by invitation | Phase 2 | 2026-06-22 | NCT06674577 | |
| Forecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD) | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, anemia, bone marrow disorder, chronic myelomonocytic leukemia, hematologic disorder, leukemia, myelodysplastic syndrome, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with single lineage dysplasia, myeloid leukemia, neoplasm | Not yet recruiting | Not stated | 2026-05-26 | NCT07607327 | |
| Monthly Dosing of Atacicept in IgAN | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Urogenital Diseases, autoimmune disease, glomerulonephritis, immune system disorder, kidney disorder, nephritis, urinary system disorder | Active, not recruiting | Phase 2 | 2026-04-13 | NCT07020923 |